Macquarie Group
WHWK

Macquarie Group’s Whitehawk Therapeutics WHWK Stock Holding History

Macquarie Group’s Portfolio WHWK Stock Details WHWK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-830
Closed -$1.21K – 1944
2024
Q2 		$1.21K Buy
+830
New +$1.54K ﹤0.01% 1834
2019
Q1 		– Sell
-227
Closed -$6K – 2078
2018
Q4 		$6K Buy
+227
New +$7.23K ﹤0.01% 2069

Other funds holding WHWK

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AI
Acuitas Investments Seattle, Washington $1.41M AUM 48.57% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Macquarie Group's WHWK Position: Q3 2024 in Review

Macquarie Group sold out of Whitehawk Therapeutics (WHWK) in Q3 2024, closing a stake of 830 shares — an estimated $1.21K sold.

Macquarie Group first reported a position in WHWK in Q4 2018 and held it in 2 quarters. The position peaked at $6K in Q4 2018. 52 funds tracked by Wall St. Rank hold WHWK as of Q3 2024.

  • Macquarie Group reported no remaining Whitehawk Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Macquarie Group sold 830 Whitehawk Therapeutics shares in Q3 2024, an estimated $1.21K.
  • Macquarie Group first reported a position in Whitehawk Therapeutics in Q4 2018 and held it in 2 quarters.
  • Macquarie Group's Whitehawk Therapeutics position peaked at $6K in Q4 2018.
  • 52 funds tracked by Wall St. Rank held Whitehawk Therapeutics as of Q3 2024.

Based on Macquarie Group's 13F filing for Q3 2024, filed 14 Nov 2024.